Inclusion Criteria:

- Histologically or cytologically confirmed unresectable locally advanced or metastatic
(stage IIIb or IV) non-small cell lung cancer (NSCLC)

- No prior systemic therapy for NSCLC

- Male or female ≥ 18 years of age

- Anticipation of more than 3 months survival

- Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 1

- Adequate organ and bone marrow function

Exclusion Criteria:

- Anticipation of need for a major surgical procedure or radiation therapy during the
study

- Remaining influence of previous therapies such as radiotherapy, surgery,
immunotherapy within 4 weeks prior to start of study treatment

- History of any of the following events within 6 months prior to start of study
treatment: myocardial infarction, severe/unstable angina pectoris,
coronary/peripheral artery bypass graft, New York Heart Association (NYHA) class ≥I
congestive heart failure (CHF), cerebrovascular accident or cerebral infarction,
pulmonary embolism, deep vein thrombosis, or other clinically significant
thromboembolic event; clinically significant pulmonary disease (eg, severe
chronic-obstructive pulmonary disease (COPD) or asthma)

- Severe edema, ascites fluid, pericardial or pleural effusion or pericardial
involvement with the tumor within 6 months prior to start of study treatment, or
which require steroid therapy/ diuretic therapy

- Subjects with brain metastasis (defined as untreated, symptomatic or requiring
steroids or anticonvulsant medications to control associated symptoms)

- Subjects with clinically significant active infection which requires antibiotic
therapy, or who are hepatitis B surface antigen (HBs)- or hepatitis C virus (HCV)- or
human immunodeficiency virus (HIV)- positive and receiving antiretroviral therapy

- Subjects with malabsorption syndrome, chronic diarrhea (lasting over 4 weeks),
inflammatory bowel disease, or partial bowel obstruction

- Diabetes mellitus requiring insulin, or a history of poor serum glucose control with
the use of non-insulin diabetes medications

- Treatment with TZDs within 4 weeks prior to start of study treatment

- History of a second malignancy, with the exception of in situ cervical cancer or
adequately treated basal cell or squamous cell carcinoma of the skin

- Poorly-controlled blood pressure as judged by the Investigator